Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2022-03-25 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于控股股东部分股份质押的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the pledge of shares by the controlling shareholder of the company. It details the number of shares pledged, the proportion of shares pledged relative to total holdings and company capital, the purpose of the pledge, and assurances about the impact on company operations and governance. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory announcement about share pledging activity, which fits the category of Capital/Financing Update (CAP). The document length is 2384 characters, which is relatively short but contains substantive information about financing activities (share pledge). Therefore, it is not a mere report publication announcement or a regulatory filing fallback. Hence, the classification is CAP with high confidence.
2022-03-25 Chinese
关于行使“20华大01”发行人赎回选择权的第二次提示性公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the exercise of the issuer's redemption option for a specific corporate bond "20 华大 01" issued by Shenzhen BGI Genomics Co., Ltd. It includes bond details, redemption dates, prices, tax information, and procedural instructions. The document states that after redemption, the bond will be delisted from the Shenzhen Stock Exchange. The content is focused on a capital/financing event related to bond redemption and delisting of the bond, not a full financial report or earnings release. The document length is 4138 characters, which is sufficient for a detailed announcement but not a full report. The primary purpose is to inform about the bond redemption and related capital structure change. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-03-21 Chinese
关于行使“20华大02”发行人赎回选择权的第二次提示性公告
Delisting Announcement Classification · 95% confidence The document is a formal announcement from Shenzhen BGI Genomics Co., Ltd. regarding the exercise of the issuer's redemption option for a specific corporate bond "20 华大 02". It details the bond's basic information, redemption date, redemption price, and the process of redemption including the cessation of trading and delisting of the bond from the Shenzhen Stock Exchange. The document is primarily about the redemption and delisting of a bond issue, with explicit mention that the bond will be delisted after redemption. This fits the category of a Delisting Announcement (DLST) because it announces the removal of the bond from the exchange following redemption. The document length is 4134 characters, which is a full announcement, not a brief note or a report publication announcement. Therefore, the correct classification is DLST with high confidence.
2022-03-21 Chinese
华大基因：关于行使“20华大01”发行人赎回选择权的第一次提示性公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement by Shenzhen BGI Genomics Co., Ltd. regarding the exercise of the issuer's redemption option for a specific corporate bond "20 华大 01". It details the bond's basic information, redemption date, redemption price, and the process of redemption including tax implications. The document also states that after redemption, the bond will be delisted from the Shenzhen Stock Exchange. The content is focused on a capital/financing update related to bond redemption and delisting of the bond, not a full financial report or earnings release. The document length is 4140 characters, which is relatively short but contains substantive information about the bond redemption event. This fits best under the category of Capital/Financing Update (CAP) because it concerns the company's financing instruments and their redemption. Although it mentions delisting of the bond, it is not a delisting announcement for the company's stock but for the bond, so CAP is more appropriate than DLST which is for stock delisting.
2022-03-14 Chinese
华大基因：关于行使“20华大02”发行人赎回选择权的第一次提示性公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shenzhen BGI Genomics Co., Ltd. regarding the exercise of the issuer's redemption option for a specific corporate bond "20 华大 02". It details the bond's basic information, redemption date, redemption price, and the process of redemption including tax implications. The document also states that after redemption, the bond will be delisted from the Shenzhen Stock Exchange. The content is focused on a capital/financing update related to bond redemption and delisting of the bond, not a full financial report or earnings release. It is not a full delisting announcement of the company's stock, but specifically about bond redemption and bond delisting. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 4136 characters, which is a full announcement, not a brief notice or a report publication announcement. Hence, CAP is the best fit with high confidence.
2022-03-14 Chinese
关于控股子公司新冠抗原检测产品医疗器械注册证变更的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Shenzhen BGI Genomics Co., Ltd. regarding a change in the medical device registration certificate for a COVID-19 antigen detection product by its subsidiary. It details the regulatory approval and changes in product usage, storage, and instructions. The document is short (1805 characters) and focuses on regulatory and product update information rather than financial data or management discussion. It does not contain financial statements, earnings data, or detailed management analysis. It is not a report but an announcement about a regulatory approval and product registration change. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for regulatory announcements that do not fit other specific categories.
2022-03-13 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.